Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Nanotherapeutics for multiple myeloma.

Zheleznyak A, Shokeen M, Achilefu S.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Nov;10(6):e1526. doi: 10.1002/wnan.1526. Epub 2018 Apr 26. Review.

PMID:
29701006
2.

Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance.

Arefanian S, Schäll D, Chang S, Ghasemi R, Higashikubo R, Zheleznyak A, Guo Y, Yu J, Asgharian H, Li W, Gelman AE, Kreisel D, French AR, Zaher H, Plougastel-Douglas B, Maggi L, Yokoyama W, Beer-Hammer S, Krupnick AS.

Oncoimmunology. 2016 Sep 27;5(12):e1238543. doi: 10.1080/2162402X.2016.1238543. eCollection 2016.

3.

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.

Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, Krupnick AS.

Nat Commun. 2016 Sep 21;7:12878. doi: 10.1038/ncomms12878.

4.

Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.

Nie X, Randolph GJ, Elvington A, Bandara N, Zheleznyak A, Gropler RJ, Woodard PK, Lapi SE.

Nucl Med Biol. 2016 Sep;43(9):534-542. doi: 10.1016/j.nucmedbio.2016.05.011. Epub 2016 May 30.

5.

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.

Lange SE, Zheleznyak A, Studer M, O'Shannessy DJ, Lapi SE, Van Tine BA.

Oncotarget. 2016 Mar 15;7(11):13082-92. doi: 10.18632/oncotarget.7552.

6.

Preclinical Positron Emission Tomographic Imaging of Acute Hyperoxia Therapy of Chronic Hypoxia during Pregnancy.

Zheleznyak A, Garbow JR, Neeman M, Lapi SE.

Mol Imaging. 2015;14:366-72.

PMID:
26162372
7.

Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.

Bandara N, Zheleznyak A, Cherukuri K, Griffith DA, Limberakis C, Tess DA, Jianqing C, Waterhouse R, Lapi SE.

Mol Imaging Biol. 2016 Feb;18(1):90-8. doi: 10.1007/s11307-015-0861-5.

8.

Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.

Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE.

Mol Pharm. 2014 Nov 3;11(11):3988-95. doi: 10.1021/mp500323d. Epub 2014 Aug 5.

9.

Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread.

Marquez BV, Zheleznyak A, Lapi SE.

J Nucl Med. 2014 May;55(5):708-9. doi: 10.2967/jnumed.113.136234. Epub 2014 Mar 24. No abstract available.

10.

Imaging of CD47 expression in xenograft and allograft tumor models.

Zheleznyak A, Ikotun OF, Dimitry J, Frazier WA, Lapi SE.

Mol Imaging. 2013 Nov-Dec;12(8). doi: 10.2310/7290.2013.00069.

PMID:
24447619
11.

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.

PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.

12.

Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems.

Ndinguri MW, Zheleznyak A, Lauer JL, Anderson CJ, Fields GB.

J Drug Deliv. 2012;2012:592602. doi: 10.1155/2012/592602. Epub 2012 Nov 14.

13.

Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Mebrahtu E, Zheleznyak A, Hur MA, Laforest R, Lapi SE.

Nucl Med Biol. 2013 Feb;40(2):190-6. doi: 10.1016/j.nucmedbio.2012.10.003. Epub 2012 Nov 12.

14.

Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.

Shokeen M, Zheleznyak A, Wilson JM, Jiang M, Liu R, Ferdani R, Lam KS, Schwarz JK, Anderson CJ.

J Nucl Med. 2012 May;53(5):779-86. doi: 10.2967/jnumed.111.100073. Epub 2012 Apr 10.

15.

Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ.

Mol Imaging Biol. 2012 Aug;14(4):500-8. doi: 10.1007/s11307-011-0512-4.

16.

In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.

Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.

J Nucl Med. 2011 Mar;52(3):470-7. doi: 10.2967/jnumed.110.082826. Epub 2011 Feb 14.

17.

Evaluation of multivalent, functional polymeric nanoparticles for imaging applications.

Shokeen M, Pressly ED, Hagooly A, Zheleznyak A, Ramos N, Fiamengo AL, Welch MJ, Hawker CJ, Anderson CJ.

ACS Nano. 2011 Feb 22;5(2):738-47. doi: 10.1021/nn102278w. Epub 2011 Jan 28.

18.

Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.

Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ.

J Nucl Med. 2009 Nov;50(11):1873-80. doi: 10.2967/jnumed.109.067140.

19.

Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.

Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani R, Liang K, Achilefu S, Anderson CJ.

J Nucl Med. 2008 Nov;49(11):1819-27. doi: 10.2967/jnumed.108.054502. Epub 2008 Oct 16.

20.

Cholesterol-independent interactions with CD47 enhance alphavbeta3 avidity.

McDonald JF, Zheleznyak A, Frazier WA.

J Biol Chem. 2004 Apr 23;279(17):17301-11. Epub 2004 Feb 13.

21.

Activation-enhanced alpha(IIb)beta(3)-integrin-cytoskeleton interactions outside of focal contacts require the alpha-subunit.

Kucik DF, O'Toole TE, Zheleznyak A, Busettini DK, Brown EJ.

Mol Biol Cell. 2001 May;12(5):1509-18.

22.

Role of CD47 as a marker of self on red blood cells.

Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP.

Science. 2000 Jun 16;288(5473):2051-4.

23.
24.

Role of cholesterol in formation and function of a signaling complex involving alphavbeta3, integrin-associated protein (CD47), and heterotrimeric G proteins.

Green JM, Zheleznyak A, Chung J, Lindberg FP, Sarfati M, Frazier WA, Brown EJ.

J Cell Biol. 1999 Aug 9;146(3):673-82.

25.

Regulation of integrin-mediated T cell adhesion by the transmembrane protein tyrosine phosphatase CD45.

Shenoi H, Seavitt J, Zheleznyak A, Thomas ML, Brown EJ.

J Immunol. 1999 Jun 15;162(12):7120-7.

26.

Effect of strong electromagnetic radiation on the screening of the Coulomb potential in a quantized magnetic field.

Zheleznyak AT, Fouladi A.

Phys Rev B Condens Matter. 1995 Mar 15;51(12):7544-7548. No abstract available.

PMID:
9977335
29.

Effect of interferon-alpha on immunoglobulin synthesis by human B cells.

Peters M, Ambrus JL, Zheleznyak A, Walling D, Hoofnagle JH.

J Immunol. 1986 Nov 15;137(10):3153-7.

PMID:
3021846

Supplemental Content

Loading ...
Support Center